<DOC>
	<DOCNO>NCT00048503</DOCNO>
	<brief_summary>The purpose study determine give tipifarnib standard treatment prevent leukemia come back ( relapse ) . Tipifarnib belong class drug call Farnesyl Transferase Inhibitors ( FTI ) . It block protein make leukemia cell grow .</brief_summary>
	<brief_title>Study Tipifarnib Postconsolidation Therapy Acute Myeloid Leukemia Patients 60 Years Older</brief_title>
	<detailed_description>The study open-label evaluation treatment tipifarnib approximately 127 subject , 60 year old , AML complete remission ( CR ) consolidation therapy . Prior enrollment , patient receive 1 2 cycle induction chemotherapy . Patients attain CR receive 1 2 cycle consolidation chemotherapy . Patients postconsolidation complete remission meet eligibility criterion offer enrollment study . Subjects enrol study treat tipifarnib A dose-modification scheme follow maintain adequate specify laboratory value minimize adverse event . Postconsolidation treatment tipifarnib continue time relapse , death , completion 24 cycle treatment , discontinuation advise study doctor . Tipifarnib , film coat , compress tablet contain 100 mg active drug , administer orally dose 300 mg ( three 100 mg film coat tablet ) take twice day 21 consecutive day 28-day cycle schedule 24 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Newlydiagnosed AML Leukemia remission Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Acute Promyelocytic Leukemia ( APL ) Previous History myelodysplasia antecedent hematologic malignancy Previous therapy farnesyl transferase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Zarnestra</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Tipifarnib</keyword>
</DOC>